Cantor Fitzgerald Reaffirms “Neutral” Rating for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ:AMED)‘s stock had its “neutral” rating reiterated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $101.00 target price on the health services provider’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 3.06% from the stock’s current price.

Other analysts have also issued research reports about the stock. William Blair lowered shares of Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday, July 1st. StockNews.com upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $100.67.

Amedisys Stock Performance

Shares of NASDAQ:AMED traded up $0.42 during midday trading on Thursday, reaching $98.00. The company’s stock had a trading volume of 23,787 shares, compared to its average volume of 312,624. The firm has a market capitalization of $3.20 billion, a PE ratio of -153.12, a P/E/G ratio of 2.40 and a beta of 0.79. Amedisys has a twelve month low of $89.55 and a twelve month high of $98.46. The stock has a fifty day moving average of $94.76 and a 200 day moving average of $93.76. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $571.41 million for the quarter, compared to analyst estimates of $565.38 million. Amedisys had a negative net margin of 0.91% and a positive return on equity of 12.85%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.00 earnings per share. On average, equities analysts expect that Amedisys will post 4.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Amedisys

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMED. Water Island Capital LLC lifted its holdings in Amedisys by 185.0% during the fourth quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock valued at $67,559,000 after purchasing an additional 461,368 shares in the last quarter. Norges Bank purchased a new position in shares of Amedisys in the fourth quarter worth about $34,032,000. Segantii Capital Management Ltd purchased a new position in shares of Amedisys in the fourth quarter worth about $32,776,000. Calamos Advisors LLC purchased a new position in shares of Amedisys in the fourth quarter worth about $23,015,000. Finally, Alpine Associates Management Inc. lifted its stake in shares of Amedisys by 23.0% in the fourth quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock worth $120,830,000 after buying an additional 237,600 shares in the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.